Grant: Alliance Grants
University of Toronto
$50,000.00
Streamlining RNA extraction for widespread COVID-19 diagnostic testing_x000d_ _x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
The ongoing COVID-19 pandemic has highlighted the importance of widespread diagnostic testing in tracing and containing viral transmission. A major bottleneck to widespread testing during this outbreak, however, has been the global shortage of commercial RNA extraction kits. These kits are used to extract the SARS-CoV-2 viral genome from patient samples before testing, and are an essential component of the majority of nucleic-acid detection assays. Shortage of RNA extraction kits has critically delayed testing in several regions globally and led to outbreaks. Canada is especially at risk because it lacks sufficient domestic supply of RNA extraction kit manufacturers, and sources most of them from other countries. Reliance on internationally sourced solutions runs greater risk of a supply bottleneck, especially during periods of an infection outbreak. In this proposal, the Chou lab is partnering with Luna Nanotech, a Toronto-based molecular diagnostics company, to develop a new class of nucleic-acid probes that streamlines RNA extraction and detection, providing three improvements over existing solutions: (i) simpler and faster protocol that does not require specialty hardware, (ii) enhanced detection sensitivity for downstream assays via target-specific enrichment, and (iii) higher cost-efficiency and scalability. We will develop and validate this technology using synthetic RNA, deactivated viruses, and patient samples, providing a well-validated reagent for clinical use. The outcome of this proposal will broadly support nucleic-acid testing technologies from centralized RT-PCR testing, point-of-care assays, to next-generating sequencing efforts via improved testing capacity and enhanced accuracy. Following completion, Luna Nanotech will also aim to integrate this new RNA extraction technology with their existing pipeline of isothermal nucleic-acid detection assay for point-of-care testing.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
550402-2020
Name nom
Chou, Leo
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Streamlining RNA extraction for widespread COVID-19 diagnostic testing_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
The ongoing COVID-19 pandemic has highlighted the importance of widespread diagnostic testing in tracing and containing viral transmission. A major bottleneck to widespread testing during this outbreak, however, has been the global shortage of commercial RNA extraction kits. These kits are used to extract the SARS-CoV-2 viral genome from patient samples before testing, and are an essential component of the majority of nucleic-acid detection assays. Shortage of RNA extraction kits has critically delayed testing in several regions globally and led to outbreaks. Canada is especially at risk because it lacks sufficient domestic supply of RNA extraction kit manufacturers, and sources most of them from other countries. Reliance on internationally sourced solutions runs greater risk of a supply bottleneck, especially during periods of an infection outbreak. In this proposal, the Chou lab is partnering with Luna Nanotech, a Toronto-based molecular diagnostics company, to develop a new class of nucleic-acid probes that streamlines RNA extraction and detection, providing three improvements over existing solutions: (i) simpler and faster protocol that does not require specialty hardware, (ii) enhanced detection sensitivity for downstream assays via target-specific enrichment, and (iii) higher cost-efficiency and scalability. We will develop and validate this technology using synthetic RNA, deactivated viruses, and patient samples, providing a well-validated reagent for clinical use. The outcome of this proposal will broadly support nucleic-acid testing technologies from centralized RT-PCR testing, point-of-care assays, to next-generating sequencing efforts via improved testing capacity and enhanced accuracy. Following completion, Luna Nanotech will also aim to integrate this new RNA extraction technology with their existing pipeline of isothermal nucleic-acid detection assay for point-of-care testing.